BRIEF published on 04/07/2026 at 07:05, 1 month 26 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 1 month 26 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 2 months 13 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 2 months 13 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 4 months 22 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 6 months 1 day ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 8 months 7 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 8 months 7 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 1 year 10 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 1 year 10 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 06/03/2026 at 10:00, 16 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 09:01, 1 hour 15 minutes ago Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 04:58, 5 hours 18 minutes ago Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026
Published on 06/03/2026 at 00:00, 10 hours 16 minutes ago Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Published on 06/03/2026 at 10:05, 11 minutes ago SLOVAKIAN BAR WINS INAUGURAL EUROPE'S 50 BEST BARS MICHTER'S ART OF HOSPITALITY AWARD
Published on 06/03/2026 at 10:00, 16 minutes ago World Bronchiectasis Conference 2026 returns to Hannover: 10 years of progress from neglected disease to global movement
Published on 06/03/2026 at 09:40, 36 minutes ago Medios AG: Contract of Executive Board Member Constantijn van Rietschoten extended ahead of schedule
Published on 06/03/2026 at 09:30, 45 minutes ago LION E-Mobility AG: Ian Mukherjee to assume Role of Chairman of the Board of Directors
Published on 06/03/2026 at 09:30, 46 minutes ago Skyborn Renewables appoints Michael Klingele as Chief Operating Officer
Published on 06/03/2026 at 08:45, 1 hour 31 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 16 hours 13 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 16 hours 34 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
Published on 06/02/2026 at 17:40, 16 hours 36 minutes ago Campus AI enters the implementation phase: Eiffage selected for deployment of shared infrastructure on the Fouju Campus in a deal worth over €120 million
Published on 06/02/2026 at 08:00, 1 day 2 hours ago EURAZEO’S PRIVATE DEBT FUND CLOSES AT RECORD €3.9 BILLION, EXCEEDING ITS INITIAL TARGET
